API | oxyphenbutazone

oxyphenbutazone (Tandearil) Report issue

Small molecule Approved ^FDA

ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW

Oxyphenbutazone is a non-steroidal anti-inflammatory drug, cyclooxygenase (prostaglandin synthetase) inhibitors which was marked under brand name tandearil for the treatment rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis. But this drug was withdrawn from markets due to bone marrow suppression. ^NCATS

Chemistry

SMILES: CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O
InChIKey: CNDQSXOVEQXJOE-UHFFFAOYSA-N
Mol. Mass: 342.4
ALogP: 3.49 Partition coefficient
ChEMBL Molecules:

oxyphenbutazone

oxyphenbutazone

levmetamfetamine

More Chemistry

Pharmacology

Mechanism of Action:
- Prostaglandin G/H synthase 1 (Homo sapiens) ^UniProt
- Prostaglandin G/H synthase 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Oral
Pro Drug: No

Organizations (2)

Research & Development (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (1)

Inflammation (approved 1960)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Arthritis, Rheumatoid ()

Osteoarthritis ()

Spondylitis, Ankylosing ()

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue